Relative abundance of BMS-665053 and its metabolites detected in bile and urine samples, collected from 0 to 7 h, of BDC rats administered an intravenous dose of 20 mg/kg
The sample preparation, analysis and data processing are described under Materials and Methods.
| Parent Drug or Metabolic Pathways | Relative Abundance | |
|---|---|---|
| Bile | Urine | |
| % | ||
| BMS-665053 | 1 | 1 |
| Pyrazinone oxidation | ||
| Met1 | 2 | 3 |
| Met2 | 11 | 14 |
| Met3 | 4 | 14 |
| GSH-related conjugates on pyrazinone | ||
| Met5 | 11 | 3 |
| Met6 | 7 | 7 |
| GSH-related conjugation on arylamine | ||
| Met9 | 11 | 3 |
| Met10 | 1 | 3 |
| Met11 | 13 | 3 |
| Glucuronidation | ||
| Met12 | 32 | 40 |
| Met13 | 7 | 7 |
| Hydroxylation | N.D. | N.D. |
N.D., not detected.